Abstract
We have cloned a human Hevin cDNA from omental adipose tissue of different patients by reverse transcription polymerase chain reaction and shown a sequence variation due to a possible polymorphism at amino acid position 161 (E/G). Hevin protein expressed in vitro showed molecular weights of approximately 75 kDa and 150 kDa, suggesting that Hevin may form a homodimer in vitro. Using Northern blots and a human expressed sequence tAg database analysis, Hevin was shown to be widely expressed in human normal or non-neoplastic diseased tissues with various levels. In contrast to this, its expression was strongly down-regulated in most neoplastic cells or tissues tested. However, neither the mechanism nor the physiological meaning of this down-regulation is known. As an initial step towards investigating the functional role of Hevin in cell growth and differentiation, we transiently or stably expressed this gene in cancer cells (HeLa 3S) that are devoid of endogenous Hevin and measured DNA synthesis (cell proliferation) by 5-bromo-2′-deoxyuridine incorporation. Hevin was shown to be a negative regulator of cell proliferation. Furthermore, we have shown that Hevin can inhibit progression of cells from G1 to S phase or prolong G1 phase. This is the first report which describes the function of Hevin in cell growth and proliferation. Through database analysis, Hevin was found to be located on chromosome 4 which contains loss of heterozygosity of many tumour suppressor genes. Taken together, these results suggest that Hevin may be a candidate for a tumour suppressor gene and a potential target for cancer diagnosis/therapy. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asamoto M, Hori T, Baba-Toriyama H, Sano M, Takahashi S, Tsuda H and Shirai T (1998) p16 gene overexpression in mouse bladder carcinomas. Cancer Lett 127: 9–13
Bendik I, Schraml P and Ludwig CU (1998) Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res 58: 626–629
Chen QR and Mixson JA (1998) Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. Front Biosci 3: 997–1004
Fulci G, Ishi N and Meir EG (1998) p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 4: 599–613
Funk SE and Sage EH (1991) The Ca2+binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cell. Proc Natl Acad Sci USA 88: 2648–2652
Girard J-P and Springer TA (1995) Cloning from purified high endothelial venule cells of Hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 2: 113–123
Girard J-P and Springer TA (1996) Modulation of endothelial cell adhesion by Hevin, an acidic protein associated with high endothelial venules. J Biol Chem 271: 4511–4517
Gossen M and Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547–5551
Gossen M, Freundlieb S, Bender G, Muller G, Hillen W and Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766–1769
Haeffner B, Baxter R, Fincham V, Downes P and Frame M (1995) Cooperation of Src homology domains in the regulated binding of phosphatidylinositol 3-kinase. J Biol Chem 270: 7937–7943
Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153: 333–339
Kutoh E, Stromstedt P-E and Poellinger L (1992) Functional interference between the ubiquitous and constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct protein–protein interaction involving the homeo subdomain of OTF-1. Mol Cell Biol 11: 4960–4969
Kutoh E, Boss O, Levasseur F and Giacobino J-P (1998) Quantification of the full length leptin receptor (OB-Rb) in human brown and white adipose tissue. Life Sci 62: 445–451
Lagadic-Gossmann D, Rissel M, Le Bot MA and Guillouzo A (1998) Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell Biol Toxicol 5: 361–373
Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D and Hsueh WA (1996) Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98: 1897–1905
Lynch TJ, Brickner J, Nakano KJ and Orias E (1995) Genetic map of randomly amplified DNA polymorphisms closely linked to the mating type locus of Tetrahymena thermophila. Genetics 141: 1315–1325
Mok S, Chan WY, Wong KK, Muto MG and Berkowitz RS (1996) SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12: 1895–1901
Nakshatri H, Bouillet P, Bhat-Nakshatri P and Chambon P (1996) Isolation of retinoic acid-repressed genes from P19 embryonal carcinoma cells. Gene 174: 79–84
Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY and Hood L (1998) Hevin, an anti-adhesive extracellular matrix protein is down-regulated in metastatic prostate adenocarcinoma. Cancer Res 58: 232–236
Obata M, Lee GH, Kanda H, Kitagawa T and Ogawa K (1997) Loss of heterozygosity at loci on chromosome 4, a common genetic event during the spontaneous immortalization of mouse embryonic fibroblasts. Mol Carcinog 19: 17–24
Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr and Iliopoulos O (1998) The von Hippel–Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 7: 959–968
Panotopoulou E, Fidas A, Apostolikas N, Besbeas S, Papas T and Kottaridis D (1997) Isolation of a cDNA clone from colon carcinoma. Anticancer Res, 3441–3444
Radany EH, Hong K, Kesharvarzi S, Lander ES and Bishop JM (1997) Mouse mammary tumor virus/v-Ha- ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. Proc Natl Acad Sci USA 94: 8664–8669
Ritland SR, Rowse GJ, Chang Y and Gendler SJ (1997) Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 57: 3520–3525
Sambrook J, Fritsch E and Maniatis T (1989). Molecular Cloning: A Laboratory Manual, 2nd edn, Cold Spring Harbor Laboratory Press, NY, USA
Santos J, Herranz M, Perez de Castro I, Pellicer A and Fernandez-Piqueras J (1998) A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4. Oncogene 17: 925–929
Shaw RJ, McClatchey AI and Jacks T (1998) Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem 273: 7757–7764
Taylor JF, Coutinho LL, Herring KL, Gallagher DS Jr, Brenneman RA, Burney N, Sanders JO, Turner JW, Smith SB, Miller RK, Savell JW and Davis SK (1998) Candidate gene analysis of GH1 for effects on growth and carcass composition of cattle. Anim Genet 29: 194–201
Vindelov LL, Christensen IJ, Keiding N, Spang-Thomsen M and Nissen NI (1983) Long-term storage of samples for flow cytometric DNA analysis. Cytometry 3: 317–322
Weinberg RA (1995) The molecular basis of oncogenes and tumor suppressor genes. Ann NY Acad Sci, (1995). 758: 331–338
Weinberg RA (1996) How cancer arises. Sci Am 275: 62–70
Yin DX, Zhu L and Schimke RT (1996) Tetracycline-controlled gene expression system achieves high-level and quantitative control of gene expression. Anal Biochem 235: 195–201
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Claeskens, A., Ongenae, N., Neefs, J. et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer 82, 1123–1130 (2000). https://doi.org/10.1054/bjoc.1999.1051
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1051
Keywords
This article is cited by
-
SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT–receptor complex
Oncogene (2018)
-
SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma
Tumor Biology (2016)
-
SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer
Tumor Biology (2011)
-
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Cancer and Metastasis Reviews (2008)
-
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Cancer and Metastasis Reviews (2008)